Education
About Us
Working with TipRanks
Follow Us
IOL Chemicals & Pharmaceuticals Ltd. (IN:IOLCP)
:IOLCP
RESEARCH TOOLSreports
Top Page
IOL Chemicals & Pharmaceuticals Ltd.
(IOLCP)
Rating:61Neutral
Price Target:
₹99.00
▲(6.00% Upside)
IOL Chemicals & Pharmaceuticals Ltd. (IOLCP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹26.49B
Dividend Yield0.89%
Average Volume (3M)181.44K
Price to Earnings (P/E)25.2
Beta (1Y)1.66
Revenue Growth2.73%
EPS Growth-11.40%
CountryIN
Employees2,777
SectorBasic Materials
Sector Strength60
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.20
Shares Outstanding293,527,500
10 Day Avg. Volume329,170
30 Day Avg. Volume181,437
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹99.00Price Target Upside6.00% Upside
Rating ConsensusHold
Number of Analyst Covering1
IOL Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model
Company DescriptionIOL Chemicals & Pharmaceuticals Ltd. (IOLCP) is an India-based company engaged in the manufacturing and supply of organic chemicals and active pharmaceutical ingredients (APIs). Operating primarily in the chemicals and pharmaceuticals sectors, IOLCP manufactures a diverse range of products that serve industries such as pharmaceuticals, agriculture, and consumer goods. The company's core products include APIs like Ibuprofen and various industrial chemicals, which are critical components in drug formulations and other industrial processes.
How the Company Makes MoneyIOLCP generates revenue through the production and sale of its APIs and specialty chemicals. The company primarily earns money by supplying these products to pharmaceutical companies and manufacturers that require high-quality raw materials for drug production and other applications. Key revenue streams include the sale of Ibuprofen API, which is one of the company's flagship products, and other industrial chemicals that cater to different sectors. Additionally, IOLCP engages in strategic partnerships and collaborations to enhance its product offerings and market reach, contributing to its financial performance. The company's focus on maintaining cost-effective manufacturing processes and expanding its product portfolio plays a significant role in sustaining its revenue growth.
IOL Chemicals & Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.79B | 21.33B | 22.02B | 21.68B | 19.46B |
| Gross Profit | 6.87B | 7.14B | 6.41B | 5.72B | 8.22B |
| EBITDA | 2.25B | 2.61B | 2.46B | 2.71B | 6.11B |
| Net Income | 1.01B | 1.34B | 1.39B | 1.68B | 4.45B |
Balance Sheet | |||||
| Total Assets | 23.82B | 22.44B | 20.22B | 19.62B | 16.10B |
| Cash, Cash Equivalents and Short-Term Investments | 2.17B | 1.15B | 186.40M | 1.20B | 3.37B |
| Total Debt | 1.17B | 327.60M | 798.10M | 439.50M | 27.30M |
| Total Liabilities | 6.94B | 6.33B | 5.14B | 5.70B | 3.50B |
| Stockholders Equity | 16.88B | 16.12B | 15.08B | 13.92B | 12.60B |
Cash Flow | |||||
| Free Cash Flow | -349.30M | 159.10M | -895.50M | -602.40M | 2.72B |
| Operating Cash Flow | 1.79B | 2.90B | 1.22B | 930.50M | 3.80B |
| Investing Cash Flow | -1.54B | -1.91B | -1.20B | -1.21B | -3.17B |
| Financing Cash Flow | 460.40M | -925.00M | -41.10M | -16.40M | -582.80M |
IOL Chemicals & Pharmaceuticals Ltd. Technical Analysis
Negative
93.40
Price Trends
92.97
Negative
81.31
Positive
78.03
Positive
Market Momentum
0.73
Positive
43.02
Neutral
21.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:IOLCP, the sentiment is Negative. The current price of 93.4 is below the 20-day moving average (MA) of 95.95, above the 50-day MA of 92.97, and above the 200-day MA of 78.03, indicating a neutral trend. The MACD of 0.73 indicates Positive momentum. The RSI at 43.02 is Neutral, neither overbought nor oversold. The STOCH value of 21.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:IOLCP.
IOL Chemicals & Pharmaceuticals Ltd. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹35.18B | 26.03 | 0.08% | 11.77% | -1.14% | ||
63 Neutral | ₹24.73B | 345.69 | 0.19% | 2.47% | -72.80% | ||
61 Neutral | ₹26.49B | 25.22 | 0.89% | 2.73% | -11.40% | ||
61 Neutral | $10.08B | 5.96 | 1.53% | 3.00% | 3.04% | -41.02% | |
54 Neutral | ₹11.02B | 118.52 | 0.87% | -19.46% | -80.73% | ||
54 Neutral | ₹32.61B | 139.85 | 0.34% | -4.57% | -87.57% | ||
48 Neutral | ₹29.19B | ― | 0.35% | -1.61% | -18.85% |
* Basic Materials Sector Average
Performance Comparison
IN:IOLCP
IOL Chemicals & Pharmaceuticals Ltd.
90.25
13.94
18.27%
IN:FAIRCHEMOR
Fairchem Organics Ltd
846.10
-458.12
-35.13%
IN:PRINCEPIPE
Prince Pipes And Fittings Ltd
299.55
-281.85
-48.48%
IN:ROSSARI
Rossari Biotech Ltd
630.90
-277.46
-30.55%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,068.15
119.00
12.54%
IN:TIRUMALCHM
Thirumalai Chemicals Limited
286.55
-27.50
-8.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.